BidaskClub upgraded shares of RadNet (NASDAQ:RDNT) from a buy rating to a strong-buy rating in a research report released on Wednesday morning, BidAskClub reports.

A number of other equities analysts have also commented on the company. TheStreet lowered RadNet from a b- rating to a c rating in a research note on Tuesday, June 4th. Zacks Investment Research lowered RadNet from a hold rating to a sell rating in a research note on Tuesday, August 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $17.75.

RadNet stock opened at $15.10 on Wednesday. The stock’s fifty day moving average price is $14.49 and its two-hundred day moving average price is $13.51. RadNet has a one year low of $9.97 and a one year high of $16.54. The company has a debt-to-equity ratio of 5.09, a current ratio of 0.80 and a quick ratio of 0.72. The firm has a market cap of $753.91 million, a PE ratio of 22.88, a price-to-earnings-growth ratio of 6.08 and a beta of 1.02.

RadNet (NASDAQ:RDNT) last posted its quarterly earnings data on Thursday, August 8th. The medical research company reported $0.10 EPS for the quarter, missing the Zacks’ consensus estimate of $0.12 by ($0.02). RadNet had a return on equity of 18.91% and a net margin of 3.33%. The company had revenue of $289.10 million for the quarter, compared to the consensus estimate of $272.36 million. During the same quarter last year, the business earned $0.11 EPS. RadNet’s revenue was up 18.3% on a year-over-year basis. Sell-side analysts expect that RadNet will post 0.33 earnings per share for the current fiscal year.

In other RadNet news, insider John V. Crues sold 50,000 shares of RadNet stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $15.07, for a total transaction of $753,500.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Michael N. Murdock sold 21,667 shares of RadNet stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $13.23, for a total value of $286,654.41. Following the transaction, the insider now directly owns 100,575 shares in the company, valued at $1,330,607.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 112,370 shares of company stock worth $1,615,605. Corporate insiders own 6.10% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in RadNet by 6.7% during the 2nd quarter. Vanguard Group Inc. now owns 2,058,540 shares of the medical research company’s stock worth $28,386,000 after buying an additional 128,738 shares during the period. Dimensional Fund Advisors LP lifted its holdings in RadNet by 0.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,581,140 shares of the medical research company’s stock worth $16,081,000 after buying an additional 12,736 shares during the period. Global Alpha Capital Management Ltd. lifted its holdings in RadNet by 31.9% during the 2nd quarter. Global Alpha Capital Management Ltd. now owns 1,183,429 shares of the medical research company’s stock worth $16,319,000 after buying an additional 286,281 shares during the period. Cortina Asset Management LLC lifted its holdings in RadNet by 32.5% during the 2nd quarter. Cortina Asset Management LLC now owns 1,167,254 shares of the medical research company’s stock worth $16,096,000 after buying an additional 286,388 shares during the period. Finally, Beck Mack & Oliver LLC lifted its holdings in RadNet by 54.8% during the 2nd quarter. Beck Mack & Oliver LLC now owns 1,065,134 shares of the medical research company’s stock worth $14,688,000 after buying an additional 376,981 shares during the period. 63.23% of the stock is currently owned by hedge funds and other institutional investors.

RadNet Company Profile

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

See Also: How do analysts define an oversold condition?

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.